PDL BioPharma, Inc. Investor Update Available Read more about PDL BioPharma, Inc. Investor Update Available
PDL BioPharma, Inc. Investor Update Available Read more about PDL BioPharma, Inc. Investor Update Available
PDL BioPharma, Inc. Investor Update Available Read more about PDL BioPharma, Inc. Investor Update Available
PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat Read more about PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat
PDL Announces Timeline for Voluntarily Delisting from Nasdaq Read more about PDL Announces Timeline for Voluntarily Delisting from Nasdaq
PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution Read more about PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business Update Read more about PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business Update
PDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020 Read more about PDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020
PDL BioPharma Completes Spin-Off of LENSAR Read more about PDL BioPharma Completes Spin-Off of LENSAR
PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020 Read more about PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020